At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,176 enrolled
Drug / intervention
SMC021 Oral Calcitonin +1 moredrug
Likely dose
SMC021 Oral Calcitonin 0.8mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Subjects With Knee Osteoarthritis
In Brief
A Phase 3 clinical trial evaluating SMC021 Oral Calcitonin and SMC021 Placebo for Osteoarthritis. Completed, enrolled 1,176 participants across 9 sites in 6 countries.
Detailed Summary
The purpose of this Phase III study is to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of patients with osteoarthritis of the knee.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis
CountriesCzechia, Denmark, Estonia, Hong Kong, Poland, Romania
CollaboratorsNovartis
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2007
First PostedJun 2007
Primary CompletionSep 2010
TodayJul 2026
First PostedJun 14, 2007
Enrollment StartMay 1, 2007
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 19.1 years ago
Interventions
SMC021 Oral Calcitonindrug
0.8mg SMC021 (Oral Calcitoinin) twice daily
SMC021 Placebodrug
Placebo orally, twice daily